{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-56.6","upperLimit":"28.1","value":"-4.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Maximum percentage change in the sum of the product of diameters (SPD) of target tumour masses assessed by contrast-enhanced CT scans of the neck, chest, abdomen and pelvis, using the Revised Response Criteria for Malignant Lymphoma.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Patients received Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.\n\nAvelumab: anti-PDL1 antibody","id":"OG000","title":"Avelumab"}],"paramType":"MEDIAN","populationDescription":"13 of the 32 patients who started treatment had available CT scans containing the target lesions at cycles 3, 6 or 8 for comparison with baseline, and these patients were included in this analysis","reportingStatus":"POSTED","timeFrame":"During trial treatment of 8 cycles (224 days), comparing baseline with cycles 3, 6 and 8","title":"Maximum Percentage Change in Sum of Product of Diameters","type":"SECONDARY","unitOfMeasure":"percentage change"}